1. Lee KY, Lee JH, Kim SJ, Yoo KH. Immunohistochemical analysis for the expression of DR5 TRAIL receptor and p53 in non-small cell lung cancer. Tuberc Respir Dis. 2008. 64:278–284.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995. 3:673–682.
3. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996. 271:12687–12690.
4. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999. 11:255–260.
5. Lee KY, Park JS, Jee YK, Rosen GD. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med. 2002. 34:462–468.
6. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005. 45:465–476.
7. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002. 16:433–443.
8. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004. 24:9695–9704.
9. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med Chem. 2007. 7:359–365.
10. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 2007. 6:2103–2112.
11. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997. 16:5386–5397.
12. Golstein P. Cell death: TRAIL and its receptors. Curr Biol. 1997. 7:R750–R753.
13. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett. 1997. 416:329–334.
14. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997. 277:818–821.
15. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 1997. 186:1165–1170.
16. Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol. 1998. 160:3–6.
17. Kastan M. On the TRAIL from p53 to apoptosis? Nat Genet. 1997. 17:130–131.
18. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death. Science. 1996. 274:782–784.
19. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996. 274:784–787.
20. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 1996. 274:787–789.
21. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol. 1999. 162:2597–2605.
22. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 1995. 270:286–290.
23. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of NF-κB transcription factor and HIV-1. EMBO J. 1991. 10:2247–2258.
24. Satake H, Suzuki K, Aoki T, Otsuka M, Sugiura Y, Yamamoto T, et al. Cupric ion blocks NF-κB activation through inhibiting the signal-induced phosphorylation of IκBα. Biochem Biophys Res Commun. 1995. 216:568–573.
25. Thanos D, Maniatis T. NF-κB: A lesson in family values. Cell. 1995. 80:529–532.
26. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo and radioresistant human chronic lymphocytic leukemia lymphocytes to TNF-α initiated apoptosis. Br J Cancer. 1998. 77:1103–1107.
27. Fiedler MA, Wernke-Dollries K, Stark JM. Inhibition of TNF-α-induced NF-κB activation and IL-8 release in A549 cells with proteasome inhibitor MG132. Am J Respir Cell Mol Biol. 1998. 19:259–268.
28. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kB activation attenuates apoptosis resistance in lymphoid cells. Blood. 1998. 91:4624–4631.
29. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature. 1993. 363:552–554.
30. Sherwood SW, Kung AL, Roitelman J, Simoni RD, Schimke RT. In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal. Proc Natl Acad Sci U S A. 1993. 90:3353–3357.
31. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995. 83:1243–1252.
32. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci U S A. 1997. 94:10057–10062.